首页> 美国卫生研究院文献>Case Reports in Nephrology and Dialysis >Oxcarbazepine Therapy for Complete Central Diabetes Insipidus
【2h】

Oxcarbazepine Therapy for Complete Central Diabetes Insipidus

机译:奥卡西平治疗完全性中枢性尿崩症

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Oxcarbazepine and carbamazepine cause hyponatremia by unknown mechanisms. We describe a patient with complete central diabetes insipidus and seizures who developed worsening hyponatremia when her dose of oxcarbazepine was increased. The patient maintained a normal serum sodium level and has had appropriately concentrated urine for 5 years on just oxcarbazepine, despite undetectable antidiuretic hormone (ADH) levels. This suggests that oxcarbazepine (or one of its metabolites) may stimulate collecting tubule V2 receptor-G protein complex independent of ADH, resulting in increased renal tubular water reabsorption. Oxcarbazepine may be useful as an alternative therapy for patients with central diabetes insipidus.
机译:奥卡西平和卡马西平通过未知机制引起低钠血症。我们描述了患有完全中枢性尿崩症和癫痫发作的患者,当奥卡西平的剂量增加时,其发展为低钠血症。尽管无法检测到抗利尿激素(ADH)的水平,但患者维持正常的血清钠水平,仅使用奥卡西平就已适当浓缩了尿液5年。这表明奥卡西平(或其代谢物之一)可能刺激独立于ADH的收集小管V2受体-G蛋白复合物,导致肾小管对水的重吸收增加。奥卡西平可作为中枢性尿崩症患者的替代疗法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号